NCT06903234View on ClinicalTrials.gov

Post-authorization Safety Study of Iptacopan in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) Using Data From the IPIG PNH Registry

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

October 1, 2029

Study Completion Date

October 1, 2029

Conditions
Hemoglobinuria, Paroxysmal
Interventions
DRUG

Iptacopan

Adult patients with PNH treated with iptacopan

Trial Locations (1)

Unknown

Novartis Investigative Site, Basel

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY